ELUXADOLINE DEMONSTRATES EFFICACY FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) WITH DIARRHOEA (IBS-D) AMONG MULTIPLE CLINICALLY RELEVANT PATIENT SUBGROUPS

被引：2
|
作者：
Lacy, B. [1 ]
Chey, W. [2 ]
Lembo, A. [3 ]
Dove, L. S. [4 ]
Covington, P. S. [4 ]
机构：
[1] Geisel Sch Med, Hanover, NH USA
[2] Univ Michigan, Ann Arbor, MI USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Furiex Pharmaceut Inc, Parsippany, NJ USA
来源：
GUT | 2016年 / 65卷
关键词：
D O I：
10.1136/gutjnl-2016-312388.69
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OC-070
引用
收藏
页码：A42 / A43
页数：2
相关论文
共 50 条
  • [1] Eluxadoline Demonstrates Efficacy for the Treatment of Irritable Bowel Syndrome (IBS) With Diarrhea (IBS-D) Among Multiple Clinically Relevant Patient Subgroups
    Lacy, Brian E.
    Chey, William
    Lembo, Anthony J.
    Dove, Leonard S.
    Covington, Paul S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S747 - S747
  • [2] Eluxadoline Demonstrates Efficacy in IBS-D Loperamide Treatment Failures
    Lacy, Brian
    Almenoff, June
    Andrae, David
    Turner, Lisa
    Lopez, Rocio
    Dove, Scott
    Covington, Paul
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S530 - S530
  • [3] EFFECT OF ELUXADOLINE ON ABDOMINAL AND BOWEL SYMPTOMS OVER TIME IN PHASE 3 CLINICAL TRIALS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D)
    Harris, L. A.
    Lucak, S.
    Chang, L.
    Dove, L. S.
    Covington, P. S.
    [J]. GUT, 2016, 65 : A122 - A123
  • [4] MAPPING THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE MEASURE (IBS-QOL) TO EQ-5D IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D)
    Bjorner, J. B.
    Rendas-Baum, R.
    Carson, R. T.
    Boer, R.
    Tucker, C.
    Andrae, D. A.
    Brazier, J. E.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A379 - A379
  • [5] A PHASE II STUDY OF LIVE BIOTHERAPEUTIC BLAUTIX IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH SUBTYPES IBS-D AND IBS-D
    Stevenson, Alex
    Glasmacher, Axel
    Markinson, Louise
    Badham, Charlie
    Quigley, Eamonn M.
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S571 - S571
  • [6] Irritable bowel syndrome: differentiating between IBS-D and IBS-O subtypes
    Lichert, Frank
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (04): : 350 - 350
  • [7] SYMPTOMATOLOGICAL PATTERN IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD), IRRITABLE BOWEL SYNDROME-DIARRHOEA (IBS-D), AND IBS-D PLUS SUDD
    Soriani, P.
    Luigi, G.
    Curlo, M.
    Parmeggiani, F.
    Malavolta, C.
    Zuppardo, R.
    Vaira, B.
    Lucarini, P.
    Lera, M.
    Franze, A.
    Cavestro, G. M.
    Carmelo, S.
    Di Mario, F.
    [J]. DIGESTIVE AND LIVER DISEASE, 2011, 43 : S245 - S245
  • [8] ORIGIN OF INCREASED FECAL SERINE PROTEASE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME AND DIARRHOEA (IBS-D)
    Garsed, K.
    Singh, G.
    Tooth, D.
    Lam, C.
    Banwait, R.
    Lingaya, M.
    Spiller, R.
    [J]. GUT, 2011, 60 : A25 - A25
  • [9] The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)
    Min, Yang Won
    Rhee, Poong-Lyul
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (03) : 136 - 142
  • [10] EFFICACY OF RIFAXIMIN IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D) AND PRIOR USE OF IBS MEDICATIONS
    Lembo, Anthony J.
    Rao, Satish S.
    Rezaie, Ali
    Heimanson, Zeev
    Pimentel, Mark
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S499 - S499
12345